A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A phase 3 trial of Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, now recruiting.
Overview
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT06084936 by Hoffmann-La Roche, with 182 participants planned, started 2023-10-22 and due to reach its primary completion in 2027-08-31. Interventions recorded: Obinutuzumab, Glofitamab, Rituximab, Bendamustine, Lenalidomide and Tocilizumab.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Rituximab and the tag pipeline.
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares Tocilizumab, Glofitamab, Obinutuzumab, Flatiron Health (Roche) and the tag pipeline.
- TrialEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Shares Glofitamab, Obinutuzumab, Flatiron Health (Roche) and the tag pipeline.
- TrialEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Shares Lenalidomide, Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
Shares Bendamustine, Obinutuzumab, Rituximab and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Glofitamab, Obinutuzumab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Bendamustine, Rituximab and the tag pipeline.